Inquire Before Buying - UK Precision Oncology Market Size & Outlook 2026-32

United Kingdom Precision Oncology Market Research Report: Forecast (2026-2032)

United Kingdom Precision Oncology Market - By Product Type (Diagnostics, Genomics, Transcriptomics, Proteomics, Epigenomics, Pharmacogenomics, Digital Pathology, Bioinformatics, T......herapeutics, Targeted Therapy, Immunotherapy, Hormone Therapy, Chemotherapy, Radiotherapy, Others), By Cancer Type (Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Others), By End User (Hospitals and Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Others),and others Read more

Healthcare
Dec 2025
Pages 136
Report Format: PDF, Excel, PPT

United Kingdom Precision Oncology Market Size: Forecast (2026- 2032)

The United Kingdom Precision Oncology Market size is valued at around USD 2.8 billion in 2025 and is projected to reach USD 4.3 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 7.19% during the forecast period, i.e., 2026-32. The United Kingdom Precision Oncology Market is accelerating rapidly as cancer prevalence rises, diagnostic activity expands, and advanced genomic technologies become central to treatment decision-making.

For instance, in April 2025, 264,880 people were assessed following an Urgent Suspected Cancer referral, averaging over 13,000 patients per working day, a 6.8% rise compared with April 2024. During the same period, 55,011 individuals commenced cancer treatment, meaning more than 2,500 patients started therapy each working day, reflecting a 4.7% month-on-month increase.

Between November 2023 and October 2024, more than 3 million people in England underwent urgent cancer checks, reflecting an increase of roughly 100,000 from the previous year and 700,000 more than pre-COVID levels.

The UK government allocated USD 2.9 billion to strengthen national imaging and diagnostic infrastructure, a move that has significantly accelerated the rollout of Community Diagnostic Centres (CDCs) across England. These centers are designed to expand testing capacity, reduce waiting times, and support earlier, more precise detection of cancer and other critical conditions.

Simultaneously, the expansion of genomic infrastructure through Genomics England and the NHS Genomic Medicine Service is embedding whole-genome sequencing, comprehensive biomarker panels, and AI-assisted genomic interpretation into routine oncology practice.

Government support continues to be a major catalyst for precision oncology expansion. For 2025/26, the UK allocated USD 2.11 billion for secondary and emergency care, including USD 768 million specifically for diagnostics. The funding will enhance existing Community Diagnostic Centres and add up to five new centers, many operating extended hours under the Elective Reform Plan. Alongside rising cancer detections and growing adoption of non-invasive genomic technologies, these investments position precision oncology for strong growth through the late 2020s.

United Kingdom Precision Oncology Market Recent Developments:

May 2025: BioNTech committed up to USD1.33 billion to expand UK personalized oncology research, supported by a USD172.05 million government grant. The plan includes two new R&D centers, over 400 jobs, and strengthened national capabilities in advanced cancer therapeutics.
May 2025: NHS England began making a “revolutionary” blood test (liquid biopsy) available across England for eligible lung- and breast-cancer patients. The test detects tiny fragments of circulating tumor DNA (ctDNA), enabling genomic results within days rather than weeks, helping patients access targeted therapies earlier and avoid some invasive biopsies or unnecessary chemotherapy. The NHS estimates up to 15,000 patients with suspected lung cancer and around 5,000 with advanced breast cancer could benefit annually.

United Kingdom Precision Oncology Market Scope:

Category	Segments
By Product Type	Diagnostics, Genomics, Transcriptomics, Proteomics, Epigenomics, Pharmacogenomics, Digital Pathology, Bioinformatics, Therapeutics, Targeted Therapy, Immunotherapy, Hormone Therapy, Chemotherapy, Radiotherapy, Others),
By Cancer Type	Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Others),
By End User	Hospitals and Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Others),and others

United Kingdom Precision Oncology Market Drivers:

Rising Cases of Cancer & Earlier Diagnosis

The sustained rise in cancer diagnoses, combined with significant improvements in early detection across England, continues to expand the demand for precision-oncology solutions. For instance, the NDRS Cancer Registration Statistics 2023 reported 354,820 newly diagnosed cases, marking the highest volume recorded to date and reflecting the upward trend extending into 2024–2025.

Meanwhile, NHS England’s most recent 2025 update further indicates a notable shift toward earlier identification between September 2023 and August 2024, 58.7% of cancers across the 13 most common tumor types were detected at stage 1 or 2, the highest rate ever achieved. This represents 206,038 diagnoses, including approximately 120,958 early-stage cases, which is 7,000 more than expected under pre-pandemic patterns.

Diagnostic activity has also intensified. For instance, in February 2025, the NHS recorded an average of 12,615 urgent suspected-cancer referrals per working day, reflecting a 33% increase over pre-COVID levels. Moreover, 76.7% of patients received a definitive cancer/no-cancer outcome within the 28-day Faster Diagnosis Standard, shortening the pathway to molecular testing and targeted treatment eligibility.

Post-2025, national plans to expand Community Diagnostic Centers, mobile screening programmes, and genomic testing capacity will further raise detection volumes and accelerate adoption of precision-oncology technologies.

Overall, rising incidence, earlier detection, and faster diagnostic confirmation collectively increase the number of patients eligible for genomics-guided therapies, solidifying this driver as a major catalyst for precision-oncology market expansion through the late 2020s.

Market Segmentation
Introduction
1. Product Definition
2. Research Process
3. Assumptions
Executive Summary
United Kingdom Precision Oncology Market Policies, Regulations, and Product Standards
United Kingdom Precision Oncology Market Supply Chain Analysis
United Kingdom Precision Oncology Market Trends & Developments
United Kingdom Precision Oncology Market Dynamics
1. Growth Drivers
2. Challenges
United Kingdom Precision Oncology Market Hotspot & Opportunities
United Kingdom Precision Oncology Market Outlook, 2022-2032
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Outlook
  1. By Product Type– Market Size & Forecast 2022-2032, USD Million
    1. Diagnostics
      1. Genomics
      2. Transcriptomics
      3. Proteomics
      4. Epigenomics
      5. Pharmacogenomics
      6. Digital Pathology
      7. Bioinformatics
    2. Therapeutics
      1. Targeted Therapy
      2. Immunotherapy
      3. Hormone Therapy
      4. Chemotherapy
      5. Radiotherapy
      6. Others
  2. By Cancer Type– Market Size & Forecast 2022-2032, USD Million
    1. Breast Cancer
    2. Colorectal Cancer
    3. Cervical Cancer
    4. Prostate Cancer
    5. Lung Cancer
    6. Others
  3. By End User– Market Size & Forecast 2022-2032, USD Million
    1. Hospitals and Clinics
    2. Diagnostic Laboratories
    3. Pharmaceutical & Biotechnology Companies
    4. Research & Academic Institutes
    5. Others
3. By Region
  1. England
  2. Scotland
  3. Wales
  4. Northern Ireland
4. By Company
  1. Company Revenue Shares
  2. Competitor Characteristics
The United Kingdom Diagnostics Precision Oncology Market Outlook, 2022-2032
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Outlook
  1. By Cancer Type– Market Size & Forecast 2022-2032, USD Million
  2. By End User– Market Size & Forecast 2022-2032, USD Million
  3. By Region
The United Kingdom Therapeutics Precision Oncology Market Outlook, 2022-2032
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Outlook
  1. By Cancer Type– Market Size & Forecast 2022-2032, USD Million
  2. By End User– Market Size & Forecast 2022-2032, USD Million
  3. By Region
United Kingdom Precision Oncology Market Key Strategic Imperatives for Success & Growth
Competition Outlook
1. Company Profiles
  1. Thermo Fisher Scientific Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  2. AstraZeneca plc
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  3. Qiagen N.V.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  4. Illumina, Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  5. GlaxoSmithKline plc (GSK)
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  6. Exact Sciences Corporation
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  7. NeoGenomics Laboratories, Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  8. GRAIL, Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  9. Guardant Health, Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  10. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Name *

Email ID *

Country *